Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy

[1] Mariotto AB(2011)Projections of the cost of cancer care in the United States: 2010-2020 J Natl Cancer Inst 103 117-128

[2] Yabroff KR(2012)Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers J Oncol Pract 8 e38s-e43s

[3] Shao Y(2014)Changing physician incentives for affordable, quality cancer care: results of an episode payment model J Oncol Pract 10 322-326

[4] Feuer EJ(2016)Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review Crit Rev Oncol Hematol 99 13-36

[5] Brown ML(2007)Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings Supporti Care Cancer 15 497-503

[6] Feinberg BA(1997)Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group Support Care Cancer 5 307-313

[7] Lang J(2011)Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting Support Care Cancer 19 131-140

[8] Grzegorczyk J(2007)Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy Cancer. 110 678-685

[9] Newcomer LN(2011)Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population Support Care Cancer 19 843-851

[10] Gould B(2011)Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States J Med Econ 14 87-98

[1] Mariotto AB(2011)Projections of the cost of cancer care in the United States: 2010-2020 J Natl Cancer Inst 103 117-128

[2] Yabroff KR(2012)Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers J Oncol Pract 8 e38s-e43s

[3] Shao Y(2014)Changing physician incentives for affordable, quality cancer care: results of an episode payment model J Oncol Pract 10 322-326

[4] Feuer EJ(2016)Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review Crit Rev Oncol Hematol 99 13-36

[5] Brown ML(2007)Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings Supporti Care Cancer 15 497-503

[6] Feinberg BA(1997)Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group Support Care Cancer 5 307-313

[7] Lang J(2011)Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting Support Care Cancer 19 131-140

[8] Grzegorczyk J(2007)Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy Cancer. 110 678-685

[9] Newcomer LN(2011)Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population Support Care Cancer 19 843-851

[10] Gould B(2011)Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States J Med Econ 14 87-98